Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial

• DOI: 10.1007/s13300-025-01723-w
• Publication Date: 2025-03-23T06:53:28Z
• Authors: Theresa Hunter Gi...; Dachuang Cao; Xiaotian Michelle...; Neena Agarwal Xavier; Jiat Ling Poon; Angela Fitch

In SURMOUNT-2, a phase 3, randomized clinical trial, tirzepatide treatment resulted in clinically meaningful reduction bodyweight among people with obesity or overweight and T2D. The current analysis evaluated the effects of on self-reported health-related quality life (HRQoL) outcomes SURMOUNT-2 participants. participants were randomly assigned (1:1:1) to receive either 10 mg (n = 312), 15 311), placebo 315) for 72 weeks as an adjunct diet exercise. Self-reported HRQoL was assessed terms changes from baseline week Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact Weight Quality Life-Lite-Clinical Trials (IWQOL-Lite-CT), EQ-5D 5-level (EQ-5D-5L) State Index (UK) associated EQ visual analog scale (VAS), Patient Global Impression Status (PGIS) Physical Activity. Post hoc analyses by categorical percent weight targets (> 0 < 5%, ≥ 10%, 15%, 20%, 25%, 30%) physical function limitations (based PGIS) tirzepatide-treated At 72, significantly larger improvements than SF-36v2 Component Summary score, functioning, bodily pain, general health, vitality, social functioning domain scores, all IWQOL-Lite-CT VAS score. Tirzepatide-treated who achieved greater showed numerically scores relative those lower reduction. For measures, at without limitations. Tirzepatide improved compared Participants achieving reductions HRQoL. NCT04657003.